CytoDyn (CYDY) announced that 10 of 11 (one failure) patients in its Phase 2b extension study of HIV therapeutic candidate PRO 140 have experienced two years of complete viral suppression (plasma HIV-1 RNA <40 copies/mL). Patients in the study received a 350 mg dose of PRO 140 once weekly via subcutaneous injection in place of their HAART (multiple antiretroviral) regimens. In the next two months, nine more patients will reach their two-year benchmarks.